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Background: The recommended tests for evaluation of glucose tolerance in cystic fibrosis are the fasting blood glucose (FBG) and the 75-g,
fasting, 2-h oral glucose tolerance test (OGTT). We compared a 50 g, non-fasting, 1-h glucose challenge test (GCT) to the standard OGTT.
Methods: During their regularly scheduled visit to the cystic fibrosis clinic, patients underwent a 50-g, non-fasting 1-h GCT and were asked
to complete a standard 75-g, fasting, 2-h OGTT within one week of their clinic visit.
Results: Fifty-seven patients underwent glucose tolerance testing. Of these, 31/57 (54%) completed both tests. Hyperglycemia was detected
on both tests in 9/31 (29%) patients, 11/31 (35%) tested positive only on the GCT, while all those with positive OGTTs had positive GCTs
( p<0.01).
Conclusions: In this study, the GCT identified all patients who meet the criteria for abnormal glucose tolerance on an OGTT. There was a
large subgroup that was positive for glucose intolerance only on the GCT. These individuals represent a distinct biochemical subgroup of
uncertain significance that warrants closer evaluation. Although the GCT can be completed in a non-fasting state and in conjunction with
regular blood work or clinic visits, the anticipated greater compliance was not seen.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Glucose tolerance testing; Oral glucose tolerance test; Glucose challenge test; Cystic fibrosis-related diabetesCystic fibrosis (CF) is the most common life-threatening
autosomal recessive disorder in Caucasians, with an
incidence of 1 in 2500 births [1]. Cystic fibrosis-related
diabetes (CFRD) is the leading co-morbidity factor in CF
patients and is associated with increased mortality, [2–4].
Evidence from clinical centers suggest that the prevalence of
impaired glucose tolerance (IGT) and CFRD are 27 to 42%
and 12 to 24% respectively, with the range in values likely
caused by differences in patient demographics and how
aggressively the diagnosis is sought between clinics [5,6].☆ Previously presented as a poster at the 2004 Cystic Fibrosis Foundation
conference, Williamsburg, Virginia, June 10, 2004.
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doi:10.1016/j.jcf.2006.10.008Evidence suggests pulmonary and nutritional markers start to
decline more rapidly months to years prior to the diagnosis of
CFRD [7,8], however they improve within months of the
start of insulin therapy [8,9]. Therefore prompt diagnosis and
treatment of CFRD is critical.
According to the Cystic Fibrosis Foundation (CFF) con-
sensus conference in 1998, the gold standard for determining
glycemic status is the 2-h, 75-g oral glucose tolerance test
(OGTT) [3]. This test requires a substantial time investment
for patients. Perhaps as a result, only 3% of physicians caring
for CF patients routinely ordered OGTTs in 1998 [10]. The
CFF recommends a random or fasting blood glucose test in
all adults at least once a year, as well as OGTT's in higher
risk subjects, however only 70.9% of adults met this recom-
mendation [11,12].ed by Elsevier B.V. All rights reserved.
Table 1
Test characteristics using the OGTT as the reference test with an OGTT
result ≥7.8 mmol/L considered a positive result
OGTT positive OGTT negative
GCT (n=31, ≥7.8 mmol/L) Test
positive
9 11
Test
negative
0 11
A1C (n=43, ≥6.0%) Test
positive
7 3
Test
negative
7 26
Sensitivity [TP/ (TP+FN)] Specificity [TN/ (TN+FP)]
GCT (n=31) 100.0% 50.0%
A1C (43) 50.0% 89.7%
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fibrotic damage to the pancreatic islets or amyloid deposition
[3,13]. This reduction in β-cells causes CF patients to have a
peak in their glucose levels at 55 to 83 min and in their
insulin levels at 70 to 150 min in response to glucose
challenge [13–16]. Therefore the 1-h, 50-g glucose chal-
lenge test (GCT) would appear to have a time frame
appropriate for assessing this glycemic excursion. This study
evaluates the GCT as a screen for glucose intolerance in CF
patients.
1. Research design and methods
Data was obtained from routine blood work performed on
patients who attended the adult CF clinic at St. Paul's
Hospital between June 2002 and May 2003. As part of their
annual assessment, patients were asked to complete a GCT
during or immediately after the clinic visit and an OGTT
within the following week. The GCT consisted of a 50-g
glucose load administered in the non-fasting state and
followed by glucose measurement 1-h later. The OGTT was
performed fasting according to the procedure described by
the WHO [17]. During both tests patients were required to
stay seated at the lab. Only 19/31 (61%) tests were
completed within the requested 1-wk period. Time delay
between tests ranged from 1 to 264 days, median 7 days,
mean 35 days. Patients previously diagnosed with CFRD
were not tested and transplant patients were followed
elsewhere. Glucose was measured on serum samples using
oxidase reagents and a Vitros 950 analyzer.
The criteria for a positive test were: ≥7.8 mmol/L for the
GCT and OGTT post-load glucose (PG), ≥6.0 mmol/L for
fasting blood glucose (FBG) and >6.0% for HbA1c (A1C).
Impaired glucose tolerance (IGT) was defined as an OGTT
result from 7.8 to 11.0 mmol/L, CFRD without FH was
defined as an OGTT result ≥11.1 mmol/L with a FBG
<7.0 mmol/L and CFRD with FH as an OGTT result
≥11.1 mmol/L with a FBG result ≥7.0 mmol/L. Impaired
fasting glucose (IFG) was defined as a FBG result
≥6.0 mmol/L and <7.0 mmol/L. The GCT was compared
to the OGTT using McNemar's test for paired data and
Fisher's Exact test for unpaired data with StatsDirect
(StatsDirect Ltd., England). The sensitivity and specificity
of tests were calculated using the OGTT as the reference test.
2. Results
Fifty-seven patients (30 male) with mean age 32.6 years
were tested. Of these patients 31/57 (54%) completed both
the GCT and the OGTT, 13/57 (23%) completed only the
GCT, and 13/57 (23%) completed only the OGTT.
Of those patients who completed both tests, 9/31 (29%)
tested positive on both, 11/31 (35%) negative on both, and
11/31 (35%) had positive results on the GCT but not on the
OGTT, while none had the reverse pattern ( p<0.01). Of
those who tested positive only on the GCT, 6/11 (55%) had aresult between 7.8 and 11.0 mmol/L and 5/11 (45%) had
results greater than 11.0 mmol/L. Two of those patients had
elevated A1C and another patient had elevated fasting blood
glucose (FBG). Of those with positive OGTT results; 1/9
(11%) was classified as CFRD with FH, 2/9 (22%) CFRD
without FH, and 6/9 (67%) IGT.
Abnormal A1C results were found in 11/56 (20%)
individuals. Of those, 6/11 (55%) completed both tests
with 6/6 (100%) testing positive on the GCT and 4/6 (66%)
testing positive on the OGTT ( p=NS). Four out of eleven
(36%) completed only the OGTT, of which 3/4 (75%) had
positive test results. One patient completed only the GCTand
tested negative on it. The GCT only missed 1/7 patients with
abnormal A1C compared to 3/10 missed by the OGTT
( p=NS).
Elevated fasting blood glucose (FBG) results were
present in 6/42 (14%) patients. Of those patients, 4/6
(67%) had elevated OGTT results, while 2/2 (100%) had
elevated GCT results ( p=NS). The 2 patients with normal
OGTT results had FBG results in the IFG range.
Compared to the OGTT, the GCT was found to have
100% sensitivity and 50% specificity while A1C had 50%
sensitivity and 89.7% specificity. These results can be seen in
Table 1.
3. Conclusions
Currently the OGTT is considered the gold standard for
assessing glucose tolerance in patients with CF. Since the
OGTT is lengthy and must be completed in the fasting state,
it would be useful to have a screen capable of reducing the
number of OGTTs performed. GCT results were elevated in
every patient who had elevated OGTT results suggesting the
GCT could fill this role. In patients with gestational diabetes,
the only group where a comparison can be made, the GCT
was found to have 83 to 88% sensitivity [18,19]. The in-
creased sensitivity found in our study is likely due to the
unique glucose kinetics found in CF patients. Regardless,
35% of patients tested negative on the GCT and our results
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OGTT. An alternate screen, proposed elsewhere, for the
OGTT selects patients with abnormal A1C or random blood
glucose, unexplained weight loss, or symptoms of hypergly-
cemia [18]. This screen had 92% sensitivity and 79%
specificity in detecting patients with CFRD in its reference
study [20]. Although this screen would reduce the number of
OGTTs performed, some patients with CFRD and many
patients with IGT would be missed and it has yet to be
validated. Fasting hyperglycemia has also been shown to
have low diagnostic value in CF patients [6]. Therefore the
GCT would seem to be the superior screen.
Compared to the OGTT, the GCT has a time frame better
able to detect brief hyperglycemic events. A large sub-group
of patients were found that had positive results on the GCT
but not on the OGTT. These patients have temporary
hyperglycemia of uncertain clinical significance. However,
the elevated FBG and A1C values present in some of these
individuals suggest that they may have clinically significant
glucose intolerance, as FBG and A1C are late, insensitive
markers of glycemic status in CF patients. This opens the
possibility that the GCT is more than just an effective screen
however further investigation is necessary. Interestingly,
gestational diabetes patients with elevated results on the GCT
and normal results on an OGTT had a higher rate of
complications than patients who had normal results on both
tests [21]. More investigation is necessary to determine
whether a similar finding could be made in CF patients.
It’s possible that practitioners would be more likely to
screen with the GCT than the OGTT. The GCT requires
less time and can be completed the same day as a routine
check-up, making it more easily incorporated into a routine
screening strategy. Surprisingly, in this study patients were
no more likely to complete the GCT than the OGTT. The
low rate of compliance may have been due to patients
being asked to complete the GCT at the end of their clinic
visit, when many patients had other tests to complete or
needed to return to work. Also since patients were asked to
complete the GCT at the time of their annual blood work,
many were unwilling to have additional blood drawn.
Giving patients the glucose load at the start of their clinic
visit and then having all blood work completed 1-h later
could reduce this problem.
In summary, we found that the GCT could be used
effectively as a screen to reduce the number of OGTTs
performed on this over-tested patient group. The GCT also
identifies a subgroup with temporary hyperglycemia of
currently unknown significance. Additionally, the GCT is
more convenient for both patient and practitioner and has the
potential to result in greater compliance with testing. This
study shows that the GCT may be a practical screening tool
to consider for some patients.References
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